A titratable, fixed-ratio combination of two well-understood and FDA approved peptides to control glycemia while mitigating the threat of hypoglycemia. A Smart solution that fits well with current and future pharmacological and device platforms.
Alan Cherrington PhD, a well respected researcher at Vanderbilt University, discovered that it is feasible to deliver insulin and glucagon together in a fixed concentration ratio. It is known that the actions of the two peptides are opposing: insulin lowers blood glucose while glucagon raises blood glucose (and is the foundation for emergency rescue from hypoglycemia). His discovery is founded on the observation that the actions of insulin and glucagon, when given together, are glucose dependent. The hormones act in concert for improved glycemic control and protection from hypoglycemia when co-administered at a critical concentration ratio.